EKE. V. Kuznetsova

E. V. Kuznetsova

*This is an algorithmically generated author record based on publicly available information.

E. V. Kuznetsova has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving the Pharmacovigilance System in Medical Organisations as an Opportunity to Enhance the Quality of Pharmacotherapy

    by M. V. Zhuravleva, S. Yu. Serebrova, E. V. Kuznetsova, T. R. Kameneva, A. V. Vlasova, A. B. Prokofiev, E. Yu. Demchenkova

    INTRODUCTION. It is essential to monitor the efficacy and safety of medicinal products as part of post-marketing surveillance to identify, assess, and prevent adverse drug reactions (ADRs). The effectiveness of pharmacovigilance depends largely on healthcare professionals’ adherence to the requirements and timeframes for reporting information to regulatory authorities.AIM. This study aimed to identify and systematise the key aspects of pharmacovigilance through an analysis of experience in organising pharmacovigilance in Moscow-based healthcare institutions in 2018–2024 to determine the focus areas for implementing, monitoring, and improving the pharmacovigilance system operating in medical organisations.DISCUSSION. The significance of pharmacovigilance systems and the need for their continuous improvement are underpinned by experience in establishing pharmacovigilance databases, including the global VigiBase database, the European Union’s EudraVigilance database, and the Eurasian Economic Union’s database. The main pharmacovigilance tools include active surveillance and collection of unsolicited/solicited reports of suspected ADRs. The Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor) has developed clear operational criteria for pharmacovigilance in medical organisations. These criteria require that medical organisations should have in-house regulations for collecting, registering, and reporting data on ADRs to Roszdravnadzor, appointing qualified persons responsible for pharmacovigilance, and obtaining access to the Pharmacovigilance database of Roszdravnadzor’s Automated Information System. This article provides a detailed description of tools for establishing an effective pharmacovigilance system in a medical organisation, as well as the focus areas for organising pharmacovigilance in medical organisations, identified by analysing the experience of a territorial entity of the Russian Federation.CONCLUSIONS. To improve the effectiveness of pharmacovigilance in medical organisations, it is necessary to ensure the quality, integrity, and completeness of data submitted in spontaneous ADR reports. Spontaneous reporting should be supplemented with active surveillance methods, including the Global Trigger Tool. The current pharmacovigilance system in Moscow demonstrates a steady increase in reporting ADRs to Roszdravnadzor.


  • Open Access

    Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation

    by M. V. Zhuravleva, K. A. Kokushkin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova

    Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant “docetaxel / carboplatin / trastuzumab + pertuzumab” regimen, considering possible subsequent adjuvant therapy with trastuzumab emtansine or trastuzumab within the Russian healthcare system.Material and methods. We searched and analyzed published clinical, epidemiological and pharmacoeconomic studies as well as regulatory and legal documents. A decision tree model was constructed to reflect the probabilities of switching to different adjuvant therapy regimens depending on the achievement of pathomorphological complete response in patients with early and locally advanced HER2+ breast cancer. The budget impact analysis was carried out comparing two primary prophylactic options, empegfilgrastim and filgrastim.Results. Despite the higher costs of prevention with empegfilgrastim compared to filgrastim (249 vs. 134 thousand rubles), due to the higher rate of achieving a pathomorphological complete response and, accordingly, fewer cases requiring adjuvant therapy with the more expensive trastuzumab emtanzine, savings of 916 thousand rubles per 1 patient per 1 year of therapy are possible. In general, prophylaxis in the target population diagnosed with early and locally advanced HER2+ breast cancer using empegfilgrastim will result in a cost reduction of 9.4 billion rubles per 1 year compared to filgrastim.Conclusion. Empegfilgrastim prophylaxis, despite its higher annual cost, is an efficient option within the Russian healthcare system. In addition to reducing the incidence of febrile neutropenia, the frequency and dose of chemotherapy are preserved, resulting in increased efficacy of the primary therapy.


  • Open Access

    Drug Cost Optimization Using Evidence-Based Decision Support Systems

    by A. V. Kryukov, A. A. Novikov, В. М. Kupchik, Е. V. Korovin, S. V. Yakovlev, E. V. Kuznetsova, Т. R. Kameneva, Е. D. Laryushkina, М. V. Zhuravleva

    The article presents an overview of specialized medical information systems that perform ABC/VEN analysis. It provides a comparison of specific examples, describes their advantages and disadvantages, as well as the possibility of automating the processes of searching for information on the proven effectiveness of drugs, selecting alternative drugs within one ATC group, selecting alternative drugs within the framework of the current clinical recommendations of the Ministry of Health of the Russian Federation, assessing drug-drug interactions, as well as the reference information from the instructions for use of the drugs.


  • Open Access

    Clinical Pharmacology of Antimicrobials: Focus on the Safety of Vancomycin and Linezolid

    by M. V. Zhuravleva, E. V. Kuznetsova, N. G. Berdnikova, A. B. Prokofiev, T. R. Kameneva, E. Yu. Demchenkova

    Scientific relevance. Vancomycin and linezolid are the antibacterial agents of choice for severe infections caused by multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). However, few studies have been conducted in Russia to analyse the safety of these medicinal products.Aim. The study aimed to compare the safety of vancomycin and linezolid using the Moscow segment of the Russian Federal Service for Surveillance in Healthcare’s database for adverse drug reaction (ADR) reports.Materials and methods. The study used information from the spontaneous reporting database for 2018–2022, which contained 147 ADR reports for vancomycin (122 reports) and linezolid (25 reports). The authors analysed the ADR distribution and assessed the statistical significance of the identified differences by sex, weight, and age of patients, conditions of medical care, route of administration, single dose, daily dose, therapy duration, ICD-10 codes, ADR severity, and ADR outcome.Results. The distribution of adverse reactions to vancomycin and linezolid by patient age was relatively uniform. Outpatient linezolid was associated with a significantly higher rate of ADRs (3 of 5 reports) than outpatient vancomycin (21 of 129 reports; p=0.0408). For ADR severity, 5 of 20 ADRs reported with linezolid required hospitalisation or prolongation of hospitalisation—considerably more than with vancomycin (16 of 94 reports; p=0.528). The average single dose of vancomycin (794 mg) was higher than that of linezolid (467 mg; p=0.007); the same was noted for average daily doses (1273 mg vs 998 mg; p=0.3664). The mean duration of treatment with linezolid before ADR onset was 5.26 days, which was significantly longer than the mean duration of treatment with vancomycin (2.44 days; p=0.0053). Oral linezolid was associated with a significantly higher ADR rate (4 of 19 cases) than oral vancomycin (5 of 96 cases; p=0.0027).Conclusions. The ADRs observed with vancomycin and linezolid were predictable and class-specific. According to the results of the ADR report analysis, adverse reactions to vancomycin and linezolid were associated with different factors. Similar results of the literature analysis confirmed this conclusion. However, according to the results of the linear regression analysis, none of the factors considered in this study had a statistically significant influence on the probability of developing an adverse reaction to vancomycin or linezolid.

  • Open Access

    Economic aspects of the fixed combinations of lipid lowering medicines in group risks patients

    by M. V. Zhuravleva, M. Yu. Frolov, E. A. Luchinin, K. A. Kokushkin, E. D. Laryushkina, T. R. Kameneva, E. V. Kuznetsova

    Relevance. Cardio-vascular diseases (CVD) are the one of the main reasons of mortality and disability. Hypercholesterinemia is a factor of CVD progression, and thus it should be corrected. Combination of statin + ezetemib is an effective option of a medical technology for this purpose. Pharmacoeconomic analysis of rosuvastatin and ezetemib fixed combination (FC) has been performed in this work in comparison with free combination (FrC) of these drugs.Materials and methods. Modelling of FC vs FrC in groups of CVD risk has been performed on 1–5 years horizon based on the local epidemiologic published data with aim of economic analysis. Efficacy of FC and FrC, direct medical costs, including cost of drugs, hospitalizations etc. were taken into account also. ICER has been calculated and compared with willingness to pay.Results. FC usage instead FrC can prevent 2960–3055 deaths and 8880–9164 admissions to hospital caused CVD. FC decrease of ambulance cost as well as others direct medical expenditures in compare with FrC treatment on 9,3 bln RUR per 5 years. ICER has been calculated and has negative (dominant) result.Conclusion. FC usage is an economic dominant technology in compare with FrC for hypercholesterolemia control.

  • Open Access

    Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow

    by E. V. Kuznetsova, M. V. Zhuravleva, I. A. Mikhailov, T. I. Kurnosova

    Objective: development of approaches to predict the likelihood of adverse reactions (ARs) when using drugs based on a comprehensive assessment of risk factors.Material and methods. We used a database containing 1,450 drug-related ARs reports from January through December 2021. A list of antibacterial drugs by international nonproprietary name (INN) with 4 or more ARs reports was selected as a reference group to perform various types of statistical analysis. A cumulative multivariate regression analysis was carried out on a database of 187 ARs notifications for 13 INN of antibacterial drugs. The study was performed in two stages. In the first stage, a statistical method was used (classical multiple regression, linear discriminant analysis, factor analysis, principal component regression, partial least squares regression, estimation of variance accuracy); at the second stage a modeling method was used. As part of the modeling stage, the integral score of the risk of ARs was presented as a sum of values for individual risk factors. Two groups of risks were proposed to be assessed: 1) intrinsic risk value for each factor (attribute), which was equal to the sum of risks of all factors (conditions) in which the drug had been used; 2) intrinsic risk value for antibacterial drugs by each INN. The total risk value was defined as the sum of the risk of the drug and all factors (conditions) in which this drug had been used.Results. The results were visualized in the form of a two-level risk-based model matrix, with a “heat map” of the risk level overlaid on it. The maximum total risk of ARs was obtained for ceftriaxone – 404.96 points, depending on patient’s gender. The minimum total risk was calculated for azithromycin and cefotaxime depending on the International Classification of Diseases (10th revision) code – 88.46 points. The proposed methodological approach also allows combining all possible combinations of drugs and conditions of their use. For example, for the use of vancomycin in hospital conditions by intravenous administration: intrinsic risk of use – 42.93 points; risk of use in hospital conditions – 183.68 points; risk when administered intravenously – 209.95 points; the total risk value in the designated situation – 436.56 points.Conclusion. The proposed approach can allow medical organizations to reduce significantly the number of ARs when using drugs by categorizing and preventing risks before they occur. It also has significant prospects of application at the federal level, given its modification on a large volume of data.


  • Oxidative stress in the pathogenesis of stroke and its correction

    by M.YU. Martynov, M.V. Zhuravleva, N.S. Vasyukova, E.V. Kuznetsova, T.R. Kameneva

    We reviewed the role of oxidative stress (OS) in the pathogenesis of ischemic (IS) and hemorrhagic stroke (HS). OS plays a major role in programmed cell death, increased permeability of the blood-brain barrier, astroglial and microglial activation, and local inflammatory response. We also reviewed the current state of neuro- and cytoprotection studies and their translation in clinical practice. With respect to experimental and clinical data the efficacy of long term administration of multimodal cytoprotective drug with antioxidant effect — ethylmethylhydroxypyridine succinate (Mexidol) is discussed during the acute and early recovery period after stroke.


  • Open Access

    Ademetionine treatment cost analysis of patients with intrahepatic cholestasis and non-alcoholic fatty disease

    by M. V. Zhuravleva, G. V. Kukushkin, E. V. Luchinina, T. V. Shelekhova, T. R. Kameneva, E. V. Kuznetsova, E. A. Luchinin

    Анализ стоимости лечения адеметионином больных внутрипечёночным холестазом и неалкогольной жировой болезнью печени


  • Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia

    by M.V. Zhuravleva, P.R. Kamchatnov, N.S. Vasyukova, V.V. Arkhipov, E.V. Kuznetsova, T.R. Kameneva, S.Yu. Serebrova

    Хроническая ишемия головного мозга (ХИМ) — распространенный синдром, который при отсутствии адекватной терапии характеризуется прогрессирующим течением, нарастанием когнитивных, эмоциональных, двигательных и других нарушений, в итоге приводящих к стойкой инвалидизации пациента. При лечении больных с ХИМ показано применение препаратов с мультимодальным нейропротективным действием. Приведены результаты анализа серии клинических исследований препаратов Мексидол и Мексидол ФОРТЕ у пациентов с ХИМ. Рассматриваются эффекты препарата в отношении когнитивных, эмоциональных, астенических, вегетативных и других проявлений ХИМ. Делается вывод о целесообразности последовательного применения препаратов Мексидол и Мексидол ФОРТЕ у таких больных.


  • Evaluation of clinical outcomes of COVID-19 in patients taking remdesivir in complex therapy in routine clinical practice

    by M.V. Zhuravleva, E.V. Kuznetsova, T.R. Kameneva, Moscow City Clinical Hospital Named After M.P. Konchalovsky, A.N. Kulikov, E.D. Laryushkina, O.M. Romashov, Moscow City Clinical Hospital No. 40, S.S. Andreev, Moscow City Clinical Hospital No. 52, et al.

    Оценка клинических исходов СOVID-19 у пациентов, получавших ремдесивир в составе комплексной терапии в рутинной клинической практике